HRP20160995T1 - Cjepivo fuzijskog proteina - Google Patents
Cjepivo fuzijskog proteina Download PDFInfo
- Publication number
- HRP20160995T1 HRP20160995T1 HRP20160995TT HRP20160995T HRP20160995T1 HR P20160995 T1 HRP20160995 T1 HR P20160995T1 HR P20160995T T HRP20160995T T HR P20160995TT HR P20160995 T HRP20160995 T HR P20160995T HR P20160995 T1 HRP20160995 T1 HR P20160995T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- fusion protein
- acid sequence
- seq
- identity
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims 12
- 102000037865 fusion proteins Human genes 0.000 title claims 12
- 229940023143 protein vaccine Drugs 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 230000021523 carboxylation Effects 0.000 claims 1
- 238000006473 carboxylation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (12)
1. Fuzijski protein sadrži najmanje dva slijeda aminokiselina, pri čemu se navedena dva slijeda aminokiselina sastoje od prvog slijeda aminokiselina koji ima najmanje 90% identičnosti slijeda sa slijedom aminokiselina prikazanim u SEQ ID NO:2, spojenim na drugi slijed aminokiselina koji ima najmanje 90% identičnosti slijeda sa slijedom aminokiselina prikazanim u SEQ ID NO:4, pri čemu je navedeni fuzijski protein sposoban potaknuti zaštitni imunitet prema Streptococcusu grupe B.
2. Fuzijski protein u skladu s patentnim zahtjevom 1, pri čemu navedeni prvi slijed aminokiselina ima najmanje 95, 96, 97, 98 ili 99% identičnosti slijeda sa slijedom aminokiselina prikazanim u SQE ID NO:2 ili pri čemu navedeni drugi slijed aminokiselina ima najmanje 95, 96, 97, 98 ili 99% identičnosti slijeda sa slijedom aminokiselina prikazanim u SQE ID NO:4.
3. Fuzijski protein u skladu s patentnim zahtjevom 1, pri čemu fuzijski protein obuhvaća slijed aminokiselina koji ima najmanje 90% identičnosti sa slijedom aminokiselina prikazanim u SEQ ID NO:6.
4. Fuzijski protein u skladu s patentnim zahtjevom 3, pri čemu fuzijski protein obuhvaća slijed aminokiselina koji ima najmanje 95% identičnosti sa slijedom aminokiselina prikazanim u SEQ ID NO:6.
5. Fuzijski protein u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu je navedeni fuzijski protein modificiran glikozilacijom, amidacijom, karboksilacijom ili fosforilacijom.
6. Cjepivo koje sadrži farmaceutski učinkovitu količinu fuzijskog proteina u skladu s bilo kojim od patentnih zahtjeva 1-5, pri čemu navedeni sastav cjepiva sposoban potaknuti zaštitni imunitet prema Streptococcusu grupe B sadrži farmaceutski prihvatljivi nosač.
7. Cjepivo u skladu s patentnim zahtjevom 6, koje nadalje sadrži adjuvans.
8. Cjepivo u skladu s bilo kojim od patentnih zahtjeva 6-7, pri čemu je navedeni fuzijski protein konjugiran s polisaharidom zbog stvaranja konjugata cjepiva.
9. Slijed nukleotida koji obuhvaća najmanje slijed nukleotida SEQ ID NO:1 udružen sa SEQ ID NO:3 ili slijed nukleotida prikazan u SEQ ID NO:5.
10. Slijed nukleotida u skladu s patentnim zahtjevom 9, pri čemu su SEQ ID NO:1 i 3 kemijski povezani, konjugirani ili umreženi.
11. Vektor koji sadrži slijed nukleotida u skladu s patentnim zahtjevom 9-10.
12. Stanica domaćin sadrži vektor u skladu s patentnim zahtjevom 11.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0700919 | 2007-04-16 | ||
| US94047307P | 2007-05-29 | 2007-05-29 | |
| PCT/SE2008/000270 WO2008127179A1 (en) | 2007-04-16 | 2008-04-14 | Fusion protein vaccine |
| EP08724181.6A EP2144924B1 (en) | 2007-04-16 | 2008-04-14 | Fusion protein vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160995T1 true HRP20160995T1 (hr) | 2016-10-21 |
Family
ID=39864173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160995TT HRP20160995T1 (hr) | 2007-04-16 | 2016-08-08 | Cjepivo fuzijskog proteina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8313748B2 (hr) |
| EP (1) | EP2144924B1 (hr) |
| CN (1) | CN101855238B (hr) |
| CA (1) | CA2684494C (hr) |
| CY (1) | CY1117896T1 (hr) |
| DK (1) | DK2144924T3 (hr) |
| ES (1) | ES2586418T3 (hr) |
| HR (1) | HRP20160995T1 (hr) |
| HU (1) | HUE028253T2 (hr) |
| LT (1) | LT2144924T (hr) |
| PL (1) | PL2144924T3 (hr) |
| PT (1) | PT2144924T (hr) |
| RU (1) | RU2487890C2 (hr) |
| SI (1) | SI2144924T1 (hr) |
| WO (1) | WO2008127179A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014018904A1 (en) * | 2012-07-26 | 2014-01-30 | Genocea Biosciences, Inc. | Fused antigen vaccines and compositions against streptococcus pneumoniae |
| CA2896552A1 (en) | 2012-10-03 | 2014-04-10 | Novartis Ag | Immunogenic compositions |
| CN103694323B (zh) * | 2013-12-09 | 2017-01-18 | 成都欧林生物科技股份有限公司 | 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用 |
| WO2017068112A1 (en) * | 2015-10-21 | 2017-04-27 | Minervax Aps | Immunogenic fusion protein |
| CA3004631A1 (en) | 2015-12-30 | 2017-07-06 | Minervax Aps | Immunogenic complex for eliciting protective immunity against group b streptococcus |
| EP3638301A1 (en) | 2017-06-16 | 2020-04-22 | GlaxoSmithKline Biologicals S.A. | Method of treatment |
| EP4061412A1 (en) | 2019-11-22 | 2022-09-28 | GlaxoSmithKline Biologicals S.A. | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
| EP4165065A2 (en) | 2020-06-12 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Gbs ferritin nanoparticles |
| EP4165064A2 (en) | 2020-06-12 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Dock tag system |
| EP4066854A1 (en) | 2021-03-29 | 2022-10-05 | MinervaX | Immunogenic fusion protein |
| CN114437235B (zh) * | 2022-01-04 | 2024-02-09 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 马链球菌马亚种8种蛋白的重组融合蛋白及其制备方法和应用 |
| CN116478953B (zh) * | 2023-06-14 | 2023-09-12 | 四川大学华西医院 | 鲍曼不动杆菌DlaT重组蛋白、制备方法及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4225579A (en) * | 1979-02-27 | 1980-09-30 | Israel Kleinberg | Means and method for improving defenses against caries |
| US4496538A (en) | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
| US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| WO1994001031A1 (fr) | 1992-07-02 | 1994-01-20 | Paul Charvet | Appareil de cuisson dans l'huile a chauffage au gaz |
| DE69331733T2 (de) * | 1992-09-16 | 2002-08-22 | Univ Tennessee Res Corp | Rekombinantes vielwertiges m-protein-vakzin |
| IL107458A0 (en) * | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
| ATE240351T1 (de) * | 1993-03-19 | 2003-05-15 | Gunnar Lindahl | Rib-protein, ein oberflächenprotein welches immunität gegen viele streptococcus-stämme der gruppe b verleiht, reinigungsverfahren für das rib-protein, testsatz und pharmazeutische zusammenstellung (arznei) |
| US6355255B1 (en) * | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| US6426074B1 (en) * | 1997-03-19 | 2002-07-30 | The Brigham And Women's Hospital Inc. | Group B Streptococcus vaccine |
| GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| JP4597123B2 (ja) * | 2003-03-13 | 2010-12-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 細菌性細胞溶解素の精製方法 |
| CA2537742C (en) | 2003-09-15 | 2014-07-22 | Chiron Corporation | Immunogenic compositions for streptococcus agalactiae |
-
2008
- 2008-04-14 EP EP08724181.6A patent/EP2144924B1/en active Active
- 2008-04-14 LT LTEP08724181.6T patent/LT2144924T/lt unknown
- 2008-04-14 DK DK08724181.6T patent/DK2144924T3/en active
- 2008-04-14 HU HUE08724181A patent/HUE028253T2/en unknown
- 2008-04-14 PT PT87241816T patent/PT2144924T/pt unknown
- 2008-04-14 SI SI200831661A patent/SI2144924T1/sl unknown
- 2008-04-14 US US12/596,249 patent/US8313748B2/en active Active
- 2008-04-14 CN CN200880020390.1A patent/CN101855238B/zh active Active
- 2008-04-14 ES ES08724181.6T patent/ES2586418T3/es active Active
- 2008-04-14 WO PCT/SE2008/000270 patent/WO2008127179A1/en active Application Filing
- 2008-04-14 PL PL08724181T patent/PL2144924T3/pl unknown
- 2008-04-14 RU RU2009142976/10A patent/RU2487890C2/ru active
- 2008-04-14 CA CA2684494A patent/CA2684494C/en active Active
-
2016
- 2016-08-08 HR HRP20160995TT patent/HRP20160995T1/hr unknown
- 2016-08-09 CY CY20161100783T patent/CY1117896T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2487890C2 (ru) | 2013-07-20 |
| SI2144924T1 (sl) | 2016-12-30 |
| PL2144924T3 (pl) | 2017-06-30 |
| US20100062015A1 (en) | 2010-03-11 |
| WO2008127179A1 (en) | 2008-10-23 |
| CA2684494A1 (en) | 2008-10-23 |
| EP2144924B1 (en) | 2016-05-11 |
| CN101855238A (zh) | 2010-10-06 |
| CN101855238B (zh) | 2014-09-17 |
| US8313748B2 (en) | 2012-11-20 |
| CY1117896T1 (el) | 2017-05-17 |
| RU2009142976A (ru) | 2011-05-27 |
| CA2684494C (en) | 2016-07-05 |
| DK2144924T3 (en) | 2016-08-22 |
| EP2144924A4 (en) | 2010-08-25 |
| EP2144924A1 (en) | 2010-01-20 |
| ES2586418T3 (es) | 2016-10-14 |
| HUE028253T2 (en) | 2017-02-28 |
| PT2144924T (pt) | 2016-08-17 |
| WO2008127179A8 (en) | 2009-07-23 |
| LT2144924T (lt) | 2016-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160995T1 (hr) | Cjepivo fuzijskog proteina | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| HRP20170530T1 (hr) | Modulacija aktivnosti proneutrofina | |
| JP2013172734A5 (hr) | ||
| WO2007048086A3 (en) | Canine influenza virus and related compositions and methods of use | |
| JP2010519252A5 (hr) | ||
| HRP20240042T1 (hr) | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci | |
| RS52535B (en) | PHARMACEUTICAL MIXTURES CONTAINING ACTIVIN-ACTRIIA ANTAGONISTS AND THEIR USE IN THE PREVENTION OR TREATMENT OF MULTIPLE MYELOMA | |
| RS50966B (sr) | Agonisti pyy i njihova upotreba | |
| HRP20230761T1 (hr) | Gdf zamke | |
| HRP20160606T1 (hr) | Pripravak mikrobakterijskih antigena | |
| HRP20231437T1 (hr) | Il-15 i il-15ralpha sushi domena na temelju modulokina | |
| WO2007091030A3 (en) | Peptide sequences and compositions | |
| IL213718A (en) | An immunogenic preparation comprising at least two saccharides individually attached to the same type of carrier and compound @ comprising @ the preparation @ the B @ L | |
| RS54204B1 (en) | NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
| IL180101A (en) | Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation | |
| ES2619332T3 (es) | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma | |
| WO2007048857A8 (es) | USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE | |
| JP2008539252A5 (hr) | ||
| WO2009025117A1 (ja) | Cdca1ペプチド及びこれを含む薬剤 | |
| ES2570760T3 (es) | Biogel | |
| EP2351843A3 (en) | Rabies virus vector systems and compositions and methods thereof |